期刊文献+

血清脂肪因子ANGPTL4水平与肥胖及2型糖尿病的相关性 被引量:19

Relationship of serum ANGPTL4 to obesity and type 2 diabetes mellitus
原文传递
导出
摘要 目的测定正常人群及新诊断的2型糖尿病患者血清中血管生成素样蛋白4(ANGVTIA)水平,探讨脂肪因子ANGPTL4与体脂参数、糖脂代谢、胰岛素抵抗的关系。方法收集正常糖调节(NGR)和新诊断2型糖尿病患者160例,按体重指数I〉25kg/m。分为正常糖调节正常体重组(NGR—NW)、正常糖调节超重/肥胖组(NGR.OW/OB)、2型糖尿病正常体重组(T2DM—NW)、2型糖尿病超重/肥胖组(T2DM—OW/OB)4个业组。检测所有研究对象血清ANGPTIA水平、空腹胰岛素和糖脂代谢参数等,并计算体重指数、腰臀比和稳态模型评估的胰岛素抵抗指数(HOMA-IR)。结果2型糖尿病组ANGPTIA水平低于NGR组[(25.75±2.85对31.08±3.35)ng/ml,P〈0.01],OW/OB组ANGPTlA水平低于NW组[(27.27±3.05对29.04±4.64)ng/ml,P〈0.01]。血清ANGPTIA与体重指数、腰臀比、空腹血糖、餐后2h血糖、HbA1C、空腹胰岛素、HOMA-IR、天冬氨酸转氨酶(AST)、谷氨酸丙氨酸氨基转移酶(ALT)、甘油三酯呈负相关(P〈0.01),与高密度脂蛋白胆固醇(HDL-C)呈正相关(P〈0.01)。多元逐步回归分析显示HbA1C、空腹胰岛素、HDL-C是血清ANGPTIA的独立相关因素(卢分别为-0.825、-0.119和3.301,均P〈0.01)。结论2型糖尿病m清ANGlYflA水平显著降低,与胰岛素水平、体脂分布、脂代谢相关,提示ANGPTL4可能在肥胖及糖脂代谢的病理生理过程中发挥一定的作用,血清ANGPTIA或许可为治疗糖尿病提供线索。 Objective To investigate the level of serum angiopoietin-like protein 4 ( ANGPTIA ) in normal subjects and patients with obesity and newly-diagnosed type 2 diabetes mellitus ( T2DM), and to explore the relationship of serum ANGPTL4 with parameters of body fat, glucose-lipid metabolism, and insulin resistance index ( HOMA-IR). Methods A total of 160 subjects with normal glucose regulation(NGR) and newly-diagnosed T2DM, were divided into 4 groups : NGR with normal weight group ( NGR-NW ) , NGR with overweight/obese group ( NGR- OW/OB) , rF2DM with normal weight group (T2DM-NW), and T2DM with overweight/obesity group (T2DM-OW/ OB) according to their body mass index (BMI). ELISA was used to determine the level of serum ANGPTIA. The weight, height, waist circunfferenee, hip circumference, waist hip ratio (WHR) , and BMI, fasting insulin ( FINS ) , lipid metabolism parameters, and insulin resistance index (HOMA-IR) were measured. Results Compare with the NGR group, the level of ANGFFIA was significantly decreased in the T2DM group [ ( 25.75 ± 2.85 vs 31.08± 3.35 ) ng/ml, P〈0.01 ], the level of ANGPTIA in OW/OB group was significantly lower than that in the NW group [ ( 27.27 ±3.05 vs 29.04 ± 4.64) ng/ml, P〈0.01 ]. Partial correlation analysis showed that serum ANGPTIA was negatively correlated with BMI, WHR, FPG, 2hPG, HbA1C, FINS, HOMA-IR, AST, ALT, and TG levels(P〈0.01 ), but positively correlated with the HDL-C ( P〈0.01 ). Multiple stepwise regression analysis showed that HbA1C, FINS, and HDL-C were independent risk factors of serum ANGPTIA (β = -0. 825, -0. 119, 3. 301, P〈0.01 ). Conclusion Sernm ANGPT1A level in T2DM and OW/OB group was lower than that in NGR and NW group. Serum ANGPTIA is associated with FINS and lipid metabolism, suggesting that it may play an important role in the pathophysiology of obesity and metabolic syndrome.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2014年第2期106-109,共4页 Chinese Journal of Endocrinology and Metabolism
关键词 血管生成素样蛋白4 脂代谢 胰岛素抵抗 糖尿病 2型 A ngiopoietin-like protein 4 Lipid metabolism disorders Insulin resistance Diabetes mellitus,type 2
  • 相关文献

参考文献8

  • 1Xu A, Lam MC, Chan KW, et al. Angiopoietin-like protein 4 decreases blood glucose and improves glucose tolerance but induces hyperlipi?demia and hepatic steatosis in mice[J]. Proc Nat[ Acad Sci USA, 2005,102 :6086-6091.
  • 2Yau MH, Wang Y. A highly conserved motif within the NH2-terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase by disrupting the enzyme dimerization[J].J Bioi Chem, 2009,284: 11942-11952.
  • 3Polonsky WH, Fisher L, Hessler D. Patient perspectives on the role of weight management in type 2 diabetes[J]. Diabetes Res Clin Pract, 2010 ,88: 151-156.
  • 4Kim HK. Hypothalamic ANGPTlA/FIAF is a novel regulator of food intake and body weight[J]. Diabetes, 201 0,59 :2772-2780.
  • 5Georgiadi A, Wang Y, Stienstra R, et al. Overexpression of angiopoietin-like protein 4 protects against atherosclerosis[J]. Arterioscl Thromb Vasc Bioi, 2013 ,33: 1529-1537.
  • 6Smart-Halajko MC. The relationship between plasma angiopoietin-like protein 4 levels, angiopoietin-like protein 4 genotype, and coronary heart disease risk[J]. Arterioscler Thromb Vasc Bioi, 20 I 0 ,30 : 2277 - 2282.
  • 7Romeo S, Pennacchio LA. Population-based resequencing of ANGPTlA uncovers variations that reduce triglycerides and increase HDL[J]. Nat Genet, 2007,39 :513-516.
  • 8王彬,赵文忠.血管生成素样蛋白4与代谢综合征的相关性探讨[J].山东医药,2012,52(7):81-83. 被引量:2

二级参考文献10

  • 1Yoon JC,Chickering TW,Rosen ED,et al.Peroxisome prolifera-tor-activated receptorγtarget gene encoding a novel angiopoietin-re-lated protein associated with adipose differentiation[J].Mol Cell Biol,2000,20(14):5343-5349.
  • 2Alberti KG,Eckel RH,Grundy SM,et al.Harmonizing the meta-bolic syndrome:a joint interim statement of the International Diabe-tes Federation Task Force on Epidemiology and Prevention;National Heart,Lung,and Blood Institute;American Heart Association;World Heart Federation;International Atherosclerosis Society;and International Association for the Study of Obesity[J].Circulation,2009,120(16):1640-1645.
  • 3Espeland MA,Craven TE,Riley WA,et al.Reliability of longitu-dinal ultrasonographic measurements of carotid intimal-medial thick-nesses.Asymptomatic Carotid Artery Progression Study Research Group[J].Stroke,1996,27(3):480-485.
  • 4Backhed F.et al.The gut microbiota as an environmental factor that regulates fat storage[J].Proc Natl Acad Sci U S A,2004,101(44):15718-15723.
  • 5Yoshida K,Shimizugawa T,Ono M,et al.Angiopoietin-like protein 4is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase[J].J Lipid Res,2002,43(11):1770-1772.
  • 6Xu A,Michael CL,Kok WC,et al.Angiopoietin-like protein4de-creases blood glucose and improves glucose tolerance but induces hy-perlipidemia and hepatic steatosis in mice Proc Natl[J].Acad Sci U S A,2005,102(17):6086-6091.
  • 7Stejskal D,Karpísek M,ReutovH,et al.Angiopoietin-like pro-tein4:development,analytical characterization,and clinical testing of a new ELISA[J].Gen Physiol Biophys,2008,27(1):59-63.
  • 8Talmud PJ,Smart M,Presswood E,et al.ANGPTL4E40K and T266M.Effects on plasma triglyceride and HDL levels,postprandial responses,and CHD risk[J].Arterioscler Thromb Vasc Biol,2008,28(12):2319-2325.
  • 9Folsom AR,Peacock JM,Demerath E,et al.Variation in AN-GPTL4and risk of coronary heart disease:the Atherosclerosis Risk in Communities Study[J].Metabolism,2008,57(11):1591-1596.
  • 10Mancia G,De Backer G,Dominiczak A,et al.2007Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hy-pertension(ESH)and of the European Society of Cardiology(ESC)[J].European Heart Journal,2007,28(12):1462-1536.

共引文献1

同被引文献128

引证文献19

二级引证文献145

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部